Navigation Links
Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
Date:7/2/2008

e a possible basis for treatment stratification to LOR-2040 and high dose cytarabine combination.

Favorable disease responses included complete responses in 35% of the 23 patients and significant cytoreduction of leukemic blasts in two others. As a further favourable outcome, these two patients and five of the patients who had complete responses were able to progress to a successful transplant, a desired outcome of successful salvage therapy. Notably, the study population included unfavourable patients with at least one adverse prognostic characteristic.

The clinical study also measured intracellular uptake of LOR-2040 in the bone marrow leukemic cells, and identified significant accumulation of the drug in the bone marrow blast cells and suggested preferential uptake of the drug by CD34+ cells, an important malignant bone marrow cell population.

The authors concluded that LOR-2040 in combination with high dose cytarabine is feasible, is active against its target R2, and "holds promise in younger patients with refractory or relapsed AML". The tolerability profile of this combination regimen was assessed as similar to that expected from high dose cytarabine alone.

"This successful clinical study has provided a detailed supporting rationale for our ongoing development program with LOR-2040 in AML", said Dr Aiping Young, Lorus' President and CEO. "This study supports Lorus' view that a highly specific targeted therapy approach can achieve efficacy with minimal impact on toxicity".

A Phase II program with LOR-2040 in this combination is presently ongoing to extend and confirm these findings in patients with refractory or relapsed AML.

About LOR-2040

LOR-2040 (formerly GTI-2040) is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. Through downregulation of R2, LOR-2040 has demonstrated strong antitumor and antimetastatic act
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Shimadzu Scientific ... Chromatograph (2D-LC), which offers a powerful separation ... The system provides a new level of ... is beneficial to scientists analyzing pharmaceutical impurities, ... products. , Comprehensive 2D-LC combines two independent ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., ... eClinical Solutions, today announced three of its experts are ... for Clinical Data Management to be held September 28 ... . The Company also announced the innovative ... overall quality in clinical trials acquired earlier this year, ...
(Date:9/17/2014)... Hussey Copper , a leader in ... copper, announces Gilmour Academy Ice Arena,s conversion of more ... solid touch surface to help protect against bacteria.  MD-Cu ... that kills greater than 99.9% of MRSA, E-coli and ... , Innovative Gilmour Academy ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... , AquaPure Genomic DNA Isolation ... range: 210 g DNA, , Method ... 1. Dissect tissue sample quickly and freeze in liquid nitrogen. Store , ... , keep tissue on ice at all times including when tissue ...
... Lisa Starr and William D. Huse , Ixsys, ... San Diego, California 92121 , , ... M13 vectors have been used extensively for subcloning mainly because the , ... DNA is a superior starting material for sequencing and in vitro ...
... and Ian Spendlove, Cancer Research,Campaign Academic Unit, Nottingham City Hospital, Hucknall Road,Nottingham NG5 1PB, ... Introduction , ... method of DNA vaccine delivery, and has been ... protective immunity in animal models to both infectious diseases and cancer , ...
Cached Biology Technology:Genomic DNA Isolation From 510 mg Marine Invertebrate Tissue 2Electrotransformation of E. coli With M13 DNA 2Electrotransformation of E. coli With M13 DNA 3Electrotransformation of E. coli With M13 DNA 4Electrotransformation of E. coli With M13 DNA 5Electrotransformation of E. coli With M13 DNA 6Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 2Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 3Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 4Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 5Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 6Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 7Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 8
(Date:9/17/2014)... Washington, USA -- "Nature has developed, very cleverly, some ... desire in optical design," said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we,ll ... in San Diego in August during a conference called ... Shaw and Rongguang Liang of the University of Arizona ...
(Date:9/17/2014)... Spanish researchers have obtained the first partial genome sequence ... pig found at the site of the Montsoriu Castle ... pig is closely related to today,s Iberian pig. Researchers ... with modern Iberian pigs. , The study, published in ... of pig species, and particularly on that of the ...
(Date:9/17/2014)... team of researchers working on a Carnegie expedition in ... rates have plummeted 40% since the mid-1970s. The scientists ... role in this perilous slowdown. , In a ... reefs, the team compared current measurements of the growth ... with similar measurements taken more than 30 years ago. ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Iberian pig genome remains unchanged after 5 centuries 2Coral growth rate plummets in 30-year comparison 2
... Veterinary Medicine have identified a gene in Labrador retriever dogs ... intense hunting or retrieving exercise, activities these dogs are trained ... hind limbs. In most cases, their legs get wobbly ... dogs may die. Labradors are the most common dog ...
... mean solar or wind power. In fact, the alternative ... engineering professor James Dumesic look a lot like the ... That,s because the new fuels are identical at the ... is where they come from. Funded by the ...
... have succeeded in tracing intricate biochemical networks involving a ... in specific tissues at particular moments in development. ... Krainer, Ph.D., both professors at CSHL and heads of ... call RNA splicing. Splicing is a key step ...
Cached Biology News:U of M researchers identify gene linked to common ailment in labrador retrievers 2New process derives 'green gasoline' from plant sugars 2CSHL team traces extensive networks regulating alternative RNA splicing 2CSHL team traces extensive networks regulating alternative RNA splicing 3CSHL team traces extensive networks regulating alternative RNA splicing 4
XEDAR Antibody...
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: